ReviewHeliyon2024
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of fermented foods for the prevention and treatment of bacterial vaginosis and vulvovaginal candidiasis.Frontiers in nutrition · 2025Pooled it
- The role of probiotics in restoring and maintaining vaginal microbiome health: a review.Infection and immunity · 2026Review
- Extracellular Vesicles fromPathogens (Basel, Switzerland) · 2026Article
- Dual effects of vaginal Candida albicans on human papillomavirus infection: A large-scale multicenter study in Chinese women.Journal of advanced research · 2026Article
- Novel Targets and Nanotechnology Approaches in Treating Vulvovaginal Candidiasis: Insights into Host-Microbe Interactions and Immunotherapy.Current pharmaceutical design · 2026Review
- Uterine microbiota dynamics and new therapeutic opportunities in gynecological diseases.American journal of translational research · 2026Review
- D-lactic acid inhibits Candida albicans associated with vulvovaginal candidiasis: in vitro and in vivo effects and underlying mechanisms.BMC microbiology · 2025Article
- Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles.NPJ biofilms and microbiomes · 2025Review
- Fluconazole-resistant vulvovaginal candidiasis in reproductive-age women: a study from Himalayan country.BMC microbiology · 2025Article
- Discovering a new paradigm: Gut microbiota as a central modulator of sexual health.World journal of gastrointestinal pathophysiology · 2025Review
- The Clinically Significant Changes in the Composition and Functional Diversity of the Vaginal Microbiome in Women with Type 2 Diabetes Mellitus.Microorganisms · 2025Article
- Vaginal Microbiota Patterns Associated with Yeast Infection in Mexican Women, a Pilot Study.Biotech (Basel (Switzerland)) · 2025Article
- Placental Molecular Expression of Different Pathogenic Vaginal Infections.International journal of molecular sciences · 2025Article
- Unlocking the Interactions Between the Whole-Body Microbiome and HPV Infection: A Literature Review.Pathogens (Basel, Switzerland) · 2025Review
- New insights in the role ofFrontiers in microbiology · 2025Article
- Advances in the interrelated nature of vaginal microecology, HPV infection, and cervical lesions.Frontiers in cellular and infection microbiology · 2025Review
- Probiotics in the Management of Vulvovaginal Candidosis.Journal of clinical medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is the second most common cause of vaginal infection globally after bacterial vaginosis (BV) and associated with adverse reproductive and obstetric outcomes, including preterm delivery, sexually transmitted infections and pelvic inflammatory disease. Although effective control of VVC is achievable with the use of traditional treatment strategies (i.e., antifungals), the possibility of drug intolerance, treatment failure and recurrence, as well as the appearance of antifungal-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.